Apple’s accidental AI feature roll-out in China risks regulatory backlash, expert says


Apple’s accidental roll-out on Tuesday of its highly anticipated Apple Intelligence feature in mainland China – which has yet to receive regulatory approval – before swiftly pulling it could raise the ire of regulators and expose the US tech giant to potential penalties, an industry expert warned.

Even though the company immediately pulled the release, the fact that Apple “pushed the feature to Chinese users before completing security evaluation and algorithm filing could be deemed as providing service without fulfilling legal compliance obligations, subjecting it to the risk of administrative penalties”, You said.

The company stunned China users in the early hours of Tuesday by making the long-overdue feature update – a package of AI-powered tools to enhance and personalise user experience across Apple devices – available to select users, according to local user accounts.

Many of them were able to download the feature – dubbed Apple Intelligence and Siri while still carrying a beta label – and use the tools on their handsets, according to social media posts.

Apple’s accidental roll-out of its Apple Intelligence feature in mainland China risks raising the ire of regulators. Photo: Shutterstock
Apple’s accidental roll-out of its Apple Intelligence feature in mainland China risks raising the ire of regulators. Photo: Shutterstock
Apple described the suite as a “personal intelligence system” integrated into iPhone, apps and Siri, offering functions such as real-time translation, photo editing and writing tools and utilities to create personalised emojis and images.
  • Related Posts

    India rations LPG supplies as Hormuz conflict disrupts West Asia imports – Firstpost

    India has rationed LPG supplies and barred piped natural gas users from buying cylinders as disruptions in the Strait of Hormuz hit fuel imports from West Asia, forcing refiners to…

    Continue reading
    Eli Lilly’s one-shot gene therapy shows promise in cutting ‘bad’ cholesterol – Firstpost

    Eli Lilly said its experimental gene-editing therapy cut LDL, or “bad,” cholesterol by up to 62% in an early-stage trial, raising hopes for a one-time treatment to help prevent heart…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *